]
October 21, 2014

TB Alliance Launches Phase 2B Clinical Trial of a Novel TB Drug Regimen that Could Cut Treatment Time by Half or More for a Majority of TB Patients

NC-005 trial tests a novel regimen of bedaquiline (Sirturo), pretomanid (formerly known as PA-824), and pyrazinamide; results could pave the way for a three-month TB treatment
October 20, 2014

Community Engagement Forum Brings Sites and Researchers Together to Improve Efforts

New tools to improve communication, monitoring, and coordination introduced
August 18, 2014

Novartis Provides Drug Candidate Compounds to TB Alliance

Exclusive worldwide license from Novartis includes a novel class of drugs that is active against drug sensitive and multi-resistant strains of tuberculosis
July 30, 2014

TB Alliance Names Elana Robertson Senior Vice President, Market Access

Robertson Will Lead Initiatives to Accelerate Adoption of New TB Drug Regimens
July 30, 2014

TB Alliance Appoints Willo Brock Senior Vice President, External Affairs

Brock Will Lead Resource Development, Advocacy, Community Engagement Efforts in Support of Promising Research Pipeline

Pages